notablelabs.com - NTBL Net Assets per Single Share

Notable Labs, Ltd. (NTBL) is actively scaling its precision oncology system to predict drug efficacy. This historical book value chart illustrates capital dynamics, where 0.74 represents the current metric. The company creates a competitive advantage through AI-driven live-cell screening and unique patents. Diagnostic reliability is ensured by strict temperature control during the express delivery of biomaterials to laboratories.

Notable Labs Ltd (NTBL) - Accounting Value per Share from 02/21/2024 to 11/02/2024

Summary analytical data breakdowns for notablelabs.com (NTBL)

- price and consensus price forecast:
Stock Price Notable Labs Inc.|NTBL - Price Target Chart
- market capitalization data:
Market Value Notable Labs, Ltd.|NTBL - Total Company Value
- book capitalization data:
Book Value per Share Notable Labs|NTBL - Company Net Assets|Market Capitalization to Book Value Ratio notablelabs.com|NTBL - Company Total Assets
- debt and liquidity data:
Debt to Equity Notable Labs, Ltd.|NTBL - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Notable Labs|NTBL - Company Total Debt|Debts to Book Capitalization Notable Labs, Ltd.
Analysis of all company metrics:Notable Labs Inc., NTBL

To find a balance between asset quality and market price, it is essential for an investor to understand the company's net assets per share, which determines the business's resilience to external shocks. This book value per share reflects the capitalization of the Notable Labs, Ltd. (NTBL) technological platform for blood cancer therapy selection, demonstrating the real value of the resources deployed in creating innovative diagnostic solutions.

Competitor analysis for Notable Labs, Ltd.

ONC - Book Value per Share|HALO: Net Assets per Single Share|Revolution Medicines (RVMD) - Net Assets per Single Share|ascentage.com (AAPG) - Net Assets per Single Share|Book Value per Share CGON|Accounting Value per Share UroGen Pharma Ltd|Book Value per Share BCAX|Book Value per Share PSNL (Personalis Genomics)|ERAS - Net Assets per Single Share|Equity per Share delcath.com DCTH|YMAB: Book Value per Share|AURA - Accounting Value per Share|Book Value per Share CADL|ARAY (Accuray, Inc.) - Net Asset Value per Share|SLS - Net Assets per Single Share|Accounting Value of a Share actuatetherapeutics.com (ACTU)|Citius Oncology (CTOR) - Accounting Value per Share|Accounting Value of a Share tuhurabio.com (HURA)|Protara - Book Value per Share|FATE - Accounting Value per Share|Aadi Bio - Accounting Value per Share|TCRX: Book Value per Share|Net Assets per Single Share championsoncology.com CSBR|XBiotech (XBIT) - Accounting Value of a Share|Book Value per Share CVM (CEL-SCI Corp.)|Net Asset Value per Share OSTX|Net Assets per Single Share Radiopharm Theranostics Limited RADX|Equity per Share ARTV (artivabio.com)|ANL: Net Assets per Single Share|VERU - Net Asset Value per Share|Accounting Value per Share Tempest Tx TPST|XLO - Book Price of a Share|RENB: Book Value per Share|Mural Oncology (MURA) - Book Value per Share|Book Value per Share Kairos Pharma Limited|Net Assets per Single Share OKUR|Net Assets per Single Share CytoMed Therapeutics (GDTC)|Net Assets per Single Share curis.com (CRIS)|APLM: Book Value per Share|THAR - Net Asset Value per Share|Accounting Value per Share Advanced Biomed Corp (ADVB)|GNPX: Accounting Value of a Share|calidibio.com (CLDI) - Net Assets per Single Share|Sunshine Biopharma Inc. (SBFM) - Net Assets per Single Share|XBIO (Xenetic Biosciences Inc.) - Book Value per Share|Book Value per Share salariuspharma.com|Book Value per Share Purple Biotech Ltd. (PPBT)|Net Assets per Single Share AONC (aoncology.com)|Net Assets per Single Share BGNE|CKPT - Net Assets per Share|Accounting Value per Share Elevation Oncology, Inc. (ELEV)|ICAD: Accounting Value of a Share|ikenaoncology.com (IKNA) - Net Assets per Single Share|Net Assets per Single Share Viracta Therapeutics, Inc.|MorphoSys Corp (MOR) - Accounting Value per Share|Book Price of a Share NAYA Biosciences Corp|Book Value per Share Ascentage Pharma Group AAPGV